Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Edward B. Garon, MD, MS (ucla)
Headshot of Edward B. Garon
Edward B. Garon

Description

Summary

This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary antitumor activity, and the PD effect of ABL503 in subjects with any progressive locally advanced (unresectable) or metastatic solid tumors who are relapsed or refractory following the last line of treatment and have no available standard of care option. This study includes 3 parts: a dose-escalation part, a dose-expansion part and tumor-expansion part

Official Title

A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, As a Single Agent in Subjects with Any Progressive Locally Advanced (unresectable) or Metastatic Solid Tumors

Keywords

Advanced Solid Tumor, Neoplasms, ABL503

Eligibility

Locations

  • UCLA accepting new patients
    Santa Monica California 90404 United States
  • USC accepting new patients
    LA California 90033 United States
  • City of Hope accepting new patients
    Duarte California 91010 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
ABL Bio, Inc.
ID
NCT04762641
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 100 study participants
Last Updated